Profound Medical Corp. (TSE:PRN - Free Report) - Raymond James issued their FY2028 earnings per share (EPS) estimates for Profound Medical in a note issued to investors on Thursday, November 7th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings per share of $4.11 for the year. The consensus estimate for Profound Medical's current full-year earnings is ($1.90) per share.
Profound Medical Stock Down 4.7 %
Shares of TSE:PRN traded down C$0.56 on Monday, reaching C$11.42. The company had a trading volume of 11,396 shares, compared to its average volume of 7,235. The firm has a market capitalization of C$279.56 million, a PE ratio of -6.88 and a beta of 0.81. The firm's 50 day simple moving average is C$10.75 and its 200-day simple moving average is C$11.55. Profound Medical has a 52-week low of C$9.55 and a 52-week high of C$16.00. The company has a current ratio of 8.61, a quick ratio of 14.98 and a debt-to-equity ratio of 16.95.
Profound Medical (TSE:PRN - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported C($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.38). The firm had revenue of C$3.06 million during the quarter, compared to the consensus estimate of C$3.42 million.
Insider Buying and Selling at Profound Medical
In other news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the company's stock in a transaction that occurred on Thursday, August 15th. The shares were bought at an average price of C$12.85 per share, for a total transaction of C$125,480.25. 8.62% of the stock is currently owned by company insiders.
Profound Medical Company Profile
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Read More
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
